Drug Approval | December 23, 2025
FDA nod to MYQORZO for obstructive hypertrophic cardiomyopathy
The drug is designed to improve functional capacity and reduce symptoms by inhibiting cardiac myosin motor activity
The drug is designed to improve functional capacity and reduce symptoms by inhibiting cardiac myosin motor activity
UK headquartered digital health scale-up strengthens global tech and innovation footprint in the country
FOP is a rare genetic disorder caused by mutations in the ALK2 kinase
The initiative is focused on a problem that continues to plague cancer outcomes in India
The approval for Exdensur (depemokimab-ulaa) comes on the back of SWIFT-1 and SWIFT-2 Phase III trials
,_Thyrocare_256_384.jpg)
Dr Kinha is a seasoned healthcare and diagnostics leader with over 17 years of experience across leading organisations in the diagnostics sector, with deep expertise in laboratory operations and quality systems
The expansion includes a larger technical and service team and increased local procurement
The new facility is expected to generate 500-600 new jobs in the region
The ChemiSphere app exemplifies how M-Trust technology transforms workflows into seamless digital experiences
The reform is set to modernise how medicines are developed, authorised, and made available across the EU
Subscribe To Our Newsletter & Stay Updated
